ClinicalTrials.gg
CompletedNCT04224194Updated May 5, 2022

Auto-injector Real Life Handling in Patients

A Phase 3 interventional study of Adalimumab in RA, sponsored by Alvotech Swiss AG. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-05.

Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who self-inject AVT02 subcutaneously (SC).

Read the detailed description

This is an autoinjector handling study to assess the ability of patients to self-inject AVT02 with the proposed autoinjector in the normal standard of care setting, and to assess the reliability of the proposed autoinjector for AVT02.

On Week 0 (Day 0) eligible patients will be trained by qualified study site personnel (Investigator-led trained injection) following the first injection. The patient will return to the clinic on Week 2 (Day 14) and will be asked to selfinject the second dose (trained self-injection). The injection will be observed by the study personnel and the patient provided any assistance necessary to complete an acceptable injection.

On Week 4 (Day 28), Week 6 (Day 42), and Week 8 (Day 56), the patient will return to clinic and will be asked to self-inject the dose without assistance but under observation of qualified trial staff (observed self-injection).

Observations of autoinjector handling events are recorded independently by both trial site staff and patients using standardized questionnaires.

Any failures to inject will be investigated to determine if they are mechanical failures of the device or due to use error of the patient.

All failures will be further investigated to determine the root cause, and where necessary, appropriate mitigation will be developed and implemented.

In the Extension period (Weeks 9 to 56), AVT02 40 mg will be administered every other week via prefilled syringe (PFS) starting from Week 10 and ending at week 54. The final efficacy evaluation is expected at Week 56.

The clinical study report (CSR) will include the data from the 8week active period. The extension phase CSR will include the data from the 48-week extension period (Weeks 9 to 56).

02

Conditions studied

  • RA

Keywords

  • auto injector pen in RA patients
03

In context

Lead sponsor

Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is male or female, 18 to 80 years of age, inclusive, at time of Screening.
  • Patients diagnosed with RA for at least 4 months and currently classified according to the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism classification criteria for RA (score ≥ 6/10).
  • Patients with moderate to severe active RA as defined by ≥ 6 swollen (out of 66) and ≥ 6 tender (out of 68) joint counts and abnormal elevation of C-Reactive Protein (CRP) (≥ 6 mg/L) and fulfills one of the two criteria at screening: a) Positive rheumatoid factor b) Evidence of one joint erosion on radiological assessment of the hands, wrists, or feet at Screening.
  • Disease Activity Score in 28 joints C-reactive protein (DAS28 CRP) score of ≥ 3.2 at Screening.
  • Eligible to receive treatment on ambulatory care.
  • RA functional Class I, II, or III.
  • Patients must be taking methotrexate (MTX) orally for ≥ 12 weeks at a stable dose of ≥ 12.5 mg in the last 4 weeks prior to screening and plan to remain on stable dose throughout the study. Patients who are on methotrexate for a minimum of 10 mg per week will be eligible if there is documented intolerance to further dose escalation.
  • If patients are using oral , they must have been on a stable dose of up to 10 mg/day prednisolone or equivalent, for ≥ 4 weeks prior to first study dose.
  • Naive to adalimumab. Prior treatment with one biologic is allowed.
  • Patient has a negative QuantiFERON test for tuberculosis (TB) during Screening.
  • Note: Patients with a positive and indeterminate QuantiFERON test are allowed if they have all of the following:
  • No evidence of active TB on chest radiograph within 3 months prior to the first dose of study drug.
  • Documented history of adequate prophylaxis initiation prior to receiving study drug in accordance with local recommendations.
  • No known exposure to active TB after most recent prophylaxis.
  • Asymptomatic at Screening and baseline (BL).
  • Patients who test positive for TB must be treated for 1 month prior to taking part in the study. Investigators should check with the medical monitor before enrolling patients receiving active treatment for TB.
  • Investigators should check with the medical monitor before enrolling such patients.
  • Sexually active women of must agree to use highly effective (hormonal contraception pills or injection or implants, sterilization, and abstinence) for the duration of the study and until 3 months after the last dose of the study drug.
  • Male patients must agree to use contraception for the duration of the study and agree not to donate sperm during and for 3 months after the last dose of study drug.
  • Evidence of a personally signed and dated document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study.
  • Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients with previous experience of self-administering medications using an autoinjector or pen (either marketed or ).
  • Patients who upon initial training are determined not to be acceptable candidates for self-administration.
  • RA with significant secondary involvement of any systemic organ (including but not limited to vasculitis, pulmonary fibrosis).
  • Prior treatment with more than 1 biologic or 1 protein kinase inhibitor DMARD for RA.
  • Previous receipt of HUMIRA® (adalimumab) or a biosimilar of adalimumab.
  • Prior treatment with TNF inhibitors for RA with lack of efficacy as per clinical judgment.
  • Treatment with DMARD other than MTX within 4 weeks prior to screening (8 weeks in case of leflunomide and azathioprine).
  • History of or current inflammatory joint disease other than RA (eg, gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic disorder (eg, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, or any overlap syndrome).
  • Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement), within 8 weeks prior to or planned during the study, or history of infected joint prosthesis within 5 years.
  • Pregnancy or breast feeding.
  • Significant cardiac (eg, ≥ III) or pulmonary disease (including obstructive pulmonary disease).
  • Evidence of uncontrolled concomitant disease (cardiac, renal, hepatic, pulmonary, metabolic, or gastro-intestinal) which in the Investigator's or medical monitor's opinion would preclude patient participation.
  • Primary or secondary immunodeficiency (history of or currently active), including known history of (HIV) infection.
  • Patient has an active and serious infection or history of infections as follows:
  • Any active infection:
  • For which non-systemic anti-infectives were used within 4 weeks prior to Day 0 (BL). Note: patients receiving topical antibiotics for facial acne do not need to be excluded.
  • Which required hospitalization or systemic anti-infective within 8 weeks prior to Day 0 (BL).
  • Recurrent or chronic infections or other active infection that, in the opinion of the Investigator or designee, might cause this study to be detrimental to the patient.
  • Invasive fungal infection or mycobacterial infection.
  • Opportunistic infections, such as listeriosis, legionellosis, or pneumocystis.
  • Patient has a history of within 5 years except for adequately treated cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.
  • Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments.
  • Has evidence (as assessed by the Investigator or designee using good clinical judgment) of active substance abuse (alcohol or drugs) within 6 months of Screening that may impact patient's ability to participate in the study.
  • Patient has a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to active substance or to any of the of Humira or AVT02.
  • Treatment with any investigational agent 90 days prior to informed consent or 5 halflives of the investigational drug (whichever is longer) and unwilling to undergo washout.
  • Previous treatment with any cell-depleting therapies, excluding cyclosporine or MTX, within previous 12 months, including investigational agents. Patients who have received cyclosporine, leflunomide, cyclophosphamide, or azathioprine in the past must have recovered from all drugrelated adverse events (AEs).
  • Patient has received live or attenuated vaccines during the 4 weeks prior to Day 0 (BL) or has the intention of receiving a live or attenuated vaccine at any time during the study.
  • Intra-articular or parenteral within 4 weeks prior to informed consent.
  • Positive tests for HIV, surface antigen, or serology.
  • \< 8.0 g/dL.
  • \< 1500 cells/mm3.
  • Absolute Lymphocyte Count \< 800 cells/mm3.
  • count \< 100 000 mm3.
  • and/or alanine aminotransferase that is persistently ≥ 2 × the . (Persistently indicates at least on 2 occasions separated by a number of days).
  • \< 50 mL/min (Cockcroft-Gault formula).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Other
    Interventional, Single arm to evaluate autoinjector handling

    To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who selfinject AVT02 (adalimumab) subcutaneously (SC).

    Combination Product: Adalimumab

Interventions

  • Combination productAdalimumab

    Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.

06

What researchers measure

Primary outcomes

  1. percentage of successful self-injections patient rated

    The percentage of successful self-injections as reported in the questionnaires completed by the patients (Patient Assessment Tool, Question 1), analyzing all self-injections occurring after the trained self-injection. The higher the % the better the result.

    Time frame: up to the Week 8

  2. percentage of successful self-injections site staff rated

    The percentage of successful self-injections as reported in the questionnaires completed by the trial site personnel (Observer Assessment Tool, Question 1) , analyzing all self-injections occurring after the trained self-injection. The higher the % the better the result.

    Time frame: up to the Week 8

Secondary outcomes

  1. frequency of any autoinjector handling events during the self-injection process

    An autoinjector handling event is any event preventing the patient from successfully, selfinjecting the full contents of the autoinjector and occurring after the training selfinjection with the autoinjector pen. The lower the number the better the result.

    Time frame: Up to week 8

07

Study locations

9 sites
  • Aleksandre Aladashvili Clinic LLC
    Tbilisi, 0102, Georgia
  • "National Institute of Endocrinology" LTD
    Tbilisi, 0159, Georgia
  • JSC "EVEX Hospitals"
    Tbilisi, 0159, Georgia
  • Tbilisi Heart and Vascular Clinic LTD
    Tbilisi, 0159, Georgia
  • Georgian Dutch Hospital LLC
    Tbilisi, 0167, Georgia
  • Communal Noncommercial Enterprise "City Clinical Hospital 8" of Kharkiv City Council
    Kharkiv, 61176, Ukraine
  • SI D. F. Chebotarev Institute of Gerontology NAMS Ukraine
    Kyiv, 04114, Ukraine
  • CU "Zaporizhzhia Regional Clinical Hospital" ZRC
    Zaporizhzhya, 69600, Ukraine
  • Municipal Institution "Zaporozhye City Clinical hospital No.10"
    Zaporozhye, 69001, Ukraine
08

References and documents

Publications

  • Damjanov N, Kirvalidze N, Kurashvili N, Berti F, Steiger M, Sobierska J, Guenzi E, Otto H, Sattar A, Haliduola HN, Edwald E, Stroissnig H. Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):781-789. doi: 10.1080/14712598.2022.2131392. Epub 2022 Oct 26. PubMed 36205514 ↗

Individual participant data

Plan to share: No — No: There is not a plan to make IPD available.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jul 2020, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2019
First posted
Jan 13, 2020
StartActual
Nov 4, 2019
Primary completionActual
Jul 8, 2020
CompletionActual
Feb 26, 2021
Last update
May 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04224194
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Nov 4, 2019
Primary completion
Jul 8, 2020
Completion
Feb 26, 2021
Last update
May 5, 2022

Study contacts

Nemanja Damjanov, Prof
principal investigator · University School of Medicine, Dir. Inst. of Rheumatology, Belgrade

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion